SciBase Holding AB (SE:SCIB)
:SCIB
Want to see SE:SCIB full AI Analyst Report?
SCIB Stock Chart & Stats
kr0.33
>-kr0.01(-1.65%)
At close: 4:00 PM EST
kr0.33
>-kr0.01(-1.65%)
Day’s Range― - ―
52-Week Rangekr16.67 - kr54.00
Previous CloseN/A
Volume1.41K
Average Volume (3M)318.73K
Market Cap
kr503.08M
Enterprise Valuekr143.37M
Total Cash (Recent Filing)kr71.25M
Total Debt (Recent Filing)kr23.93M
Price to Earnings (P/E)―
Beta-0.07
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-20.94
Shares Outstanding10,225,300
10 Day Avg. Volume218,776
30 Day Avg. Volume318,725
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)18.68
Price to Sales (P/S)3.07
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.33
Revenue Forecast (FY)kr69.80M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSteady multi-year revenue growth indicates expanding clinical adoption of the Nevisense platform and increasing test volumes. For a device-plus-consumables model this scaling creates a larger base of recurring usage-linked sales, improving prospects for operating leverage and long-term unit economics.
Gross MarginA near-60% gross margin is a structural strength for a diagnostics company with device and consumable sales. High product-level margins mean incremental revenue can flow to profit as fixed costs are spread, supporting eventual margin recovery once installed base and test volume scale sustainably.
Manageable LeverageModerate leverage provides greater financial flexibility than peers with heavier debt loads. With debt relatively contained and positive equity, the balance sheet can support near-term commercialization and follow-on investments with lower immediate insolvency risk, easing refinancing pressure while revenues scale.
Bears Say
Large Operating LossesVery large negative operating and net margins show the cost base far exceeds current revenue, a structural issue rather than short-term variability. Persistent deep losses require continual funding, raise dilution risk, and mean profitability remains uncertain until revenue growth materially outpaces fixed and operating costs.
Severe Cash BurnSustained ~-85M TTM cash outflows indicate the business is reliant on external financing to maintain operations and commercial expansion. Even if FCF deterioration eased, ongoing negative cash generation constrains strategic flexibility and heightens execution risk if capital access tightens or terms worsen.
Poor Returns & Equity VolatilityDeeply negative ROE and volatile equity reflect prior dilution and weak capital efficiency. This undermines investor confidence and can increase the cost of future funding. Structurally, it signals the company must materially improve profitability or face repeated equity raises that dilute returns.
SciBase Holding AB News
SCIB FAQ
What was SciBase Holding AB’s price range in the past 12 months?
SciBase Holding AB lowest stock price was kr16.67 and its highest was kr54.00 in the past 12 months.
What is SciBase Holding AB’s market cap?
SciBase Holding AB’s market cap is kr503.08M.
When is SciBase Holding AB’s upcoming earnings report date?
SciBase Holding AB’s upcoming earnings report date is Aug 19, 2026 which is in 70 days.
How were SciBase Holding AB’s earnings last quarter?
SciBase Holding AB released its earnings results on May 07, 2026. The company reported -kr3 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.
Is SciBase Holding AB overvalued?
According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued.
Does SciBase Holding AB pay dividends?
SciBase Holding AB does not currently pay dividends.
What is SciBase Holding AB’s EPS estimate?
SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SciBase Holding AB have?
SciBase Holding AB has 10,225,300 shares outstanding.
What happened to SciBase Holding AB’s price movement after its last earnings report?
SciBase Holding AB reported an EPS of -kr3 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 6.618%.
Which hedge fund is a major shareholder of SciBase Holding AB?
Currently, no hedge funds are holding shares in SE:SCIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SciBase Holding AB
SciBase Holding AB (publ), a medical technology firm founded in 1998 and headquartered in Sundbyberg, Sweden, specializes in the global development and distribution of instruments for diagnosing skin cancer and other dermatological issues. Their key offerings, Nevisense and Nevisense Go, comprise a point-of-care platform designed for the detection of melanoma and non-melanoma skin cancers, as well as for evaluating skin barrier function. The company also maintains a collaborative agreement with the Advanced Dermatology and Cosmetic Surgery (ADCS) group.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
Luxbright AB
―
Arcoma AB
―
Neola Medical AB
―
Iconovo AB
―